The recent inauguration of Lifenity Group management in Dubai
Lifenity Group announces the launch of an integrated clinical pathology and genomics laboratory in the Middle East. This state-of-the-art laboratory in Dubai will focus on the study of the profound effects of genomic variation on disease susceptibility as well as disease onset and progression.
Located in Jumeirah Lakes Towers (JLT), the facility was inaugurated today in the presence of Chairman Vijay Dhawangale; Lifenity Group Managing Director Nikhil Karkera and Partner Bankim Nanavati.
Commenting on the importance of the laboratory, Dhawangale said: “We are proud to launch our integrated clinical pathology and genomics laboratory, which demonstrates our commitment to revolutionizing healthcare. Our integrated approach, cutting-edge technology and A comprehensive testing service will serve patients “in the field of genomic diagnostics. Through impactful research, our goal is to advance preventive and predictive healthcare and make it accessible to everyone. “
Lifenity offers comprehensive in-house testing services to meet the complete diagnostic needs of patients. These services include LCMS (Complete Vitamin Analysis), Hematology, Biochemistry, Microbiology, Mycology, Serology, Preventive Care, Immunochemistry, Molecular and Diagnostic Genomics.
The lab will study a variety of diseases and conditions with respect to genomic variation and disease susceptibility. It will leverage Illumina and Thermo-Fisher microarrays for population-scale screening of genetic variants and precision medicine, and next-generation sequencing to examine genomic variants relevant to predicting healthcare, genetic disorders, cancer and infectious disease. The laboratory will also conduct cardiac and gastrointestinal risk panels, as well as correlation studies of current health parameters.
In addition, Lifenity aims to complement its existing research by providing patients with a range of genetic services, including routine physical exams, predictive and diagnostic genetic testing, and monitoring of disease progression. These enable individuals to identify health problems, learn about genetic conditions, confirm diagnoses and track the effects of treatments. The group aims to promote healthy living through the continuous development of needs-based genetic testing.
Dhawangale added, “Lifenity is passionate about partnering with healthcare organizations in the region to provide genetic services for predictive therapy and preventive care. As a global referral laboratory, Lifenity works by providing the information, education and and communication to support healthcare organizations.
“We have extensive experience in large-scale diagnostics, bringing invaluable expertise to large-scale screening, diagnostics, and healthcare delivery,” said Karkera. Collaboration with our experts, government agencies, and technology partners enhances the experimental Chamber capacity ensures excellent performance.
“Accessible and actionable genetic care is paramount at Lifenity Genomics Laboratories. We prioritize ongoing patient engagement, providing consultation through skilled physicians and genetic counselors. We are committed to providing comprehensive support to ensure that patients Health throughout the testing process,” he further added.
Lifenity Group’s global footprint spans India, Maldives, UK and 14 countries in Africa. The group is actively exploring expansion opportunities in the EU and Latin America regions, strengthening its commitment to global expansion.